Goel et al. classified the mutations common in MDS and MDS progression to leukemia into the following main groups: spliceosome genes (SF3B1, U2AF1, SRSF2, EZH2), epigenetic modifiers (TET2, DNMT3A, ASXL1), transcription factors (RUNX1, CEBPA, GATA2), and cell signaling genes (NRAS, KRAS, FLT3) [17]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.